Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Change in Acquisitions & Divestments (2018 - 2022)

Historic Change in Acquisitions & Divestments for Spero Therapeutics (SPRO) over the last 5 years, with Q2 2022 value amounting to $49.9 million.

  • Spero Therapeutics' Change in Acquisitions & Divestments rose 14327.32% to $49.9 million in Q2 2022 from the same period last year, while for Mar 2023 it was $49.9 million, marking a year-over-year decrease of 1166.08%. This contributed to the annual value of $60.8 million for FY2022, which is 1790.37% up from last year.
  • Latest data reveals that Spero Therapeutics reported Change in Acquisitions & Divestments of $49.9 million as of Q2 2022, which was up 14327.32% from $10.9 million recorded in Q1 2022.
  • In the past 5 years, Spero Therapeutics' Change in Acquisitions & Divestments registered a high of $50.6 million during Q1 2019, and its lowest value of $2.0 million during Q4 2020.
  • For the 5-year period, Spero Therapeutics' Change in Acquisitions & Divestments averaged around $20.7 million, with its median value being $18.3 million (2020).
  • Per our database at Business Quant, Spero Therapeutics' Change in Acquisitions & Divestments plummeted by 8561.15% in 2020 and then surged by 35120.0% in 2021.
  • Over the past 5 years, Spero Therapeutics' Change in Acquisitions & Divestments (Quarter) stood at $35.5 million in 2018, then crashed by 76.03% to $8.5 million in 2019, then crashed by 76.47% to $2.0 million in 2020, then soared by 250.0% to $7.0 million in 2021, then surged by 612.44% to $49.9 million in 2022.
  • Its last three reported values are $49.9 million in Q2 2022, $10.9 million for Q1 2022, and $7.0 million during Q4 2021.